GPCR Therapeutics, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.gpcr.co.kr
Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05561751
- Locations
- 🇺🇸
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Florida (UF) - Shands Cancer Center, Gainesville, Florida, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02104427
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01458288
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01018979
- Locations
- 🇨🇳
Buddist Tzu Chi General Hospital, Hualien, Taiwan
🇨🇳Chang-Gung Memorial Hospital Chiayi, Chiayi, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- GPCR Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00822341
- Locations
- 🇺🇸
PAREXEL Clinical Pharmacology Research Unit Harbor Hospital Center, Baltimore, Maryland, United States
© Copyright 2024. All Rights Reserved by MedPath